About 215 results

ALLMedicine™ Mevalonate Kinase Deficiency Center

Research & Reviews  73 results

Fitness to Serve in the Armed Forces and Internal Medicine: A Retrospective Study.
Military Medicine; Lhaiba M, Caré W et. al.

Apr 13th, 2022 - Assessment of the medical fitness to serve in the armed forces has two objectives: to prevent the military operations from being jeopardized by a medical issue, and to protect soldiers from the sequelae of diseases that could become complicated in...

Uveitis, glaucoma, and cataract with mevalonate kinase deficiency.
Journal of AAPOS : the Official Publication of the Americ... Agarwal N, Kothari M

Feb 15th, 2022 - We report 7 years of follow-up data on ocular findings in a 2-month-old boy who presented with early-onset bilateral granulomatous panuveitis with subsequent development of secondary glaucoma and total cataract, along with multisystem involvement....

Vasculitis in a patient with mevalonate kinase deficiency (MKD): a case report.
Pediatric Rheumatology Online Journal; Omoyinmi E, Rowczenio D et. al.

Nov 24th, 2021 - Mevalonate kinase deficiency (MKD) is a rare autoinflammatory condition caused by biallelic loss-of-function (LOF) mutations in mevalonate kinase (MVK) gene encoding the enzyme mevalonate kinase. Patients with MKD display a variety of non-specific...

Canakinumab improves patient-reported outcomes in children and adults with autoinflamma...
Clinical and Experimental Rheumatology; Lachmann HJ, Lauwerys B et. al.

Oct 9th, 2021 - To evaluate the effect of canakinumab on health-related quality of life (HRQoL), work/school and social life of patients with autoinflammatory recurrent fever syndromes, including colchicine-resistant familial Mediterranean fever, mevalonate kinas...

Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficie...
Rheumatology (Oxford, England); Jeyaratnam J, Simon A et. al.

Sep 24th, 2021 - To evaluate the long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency during the open label extension (weeks 41-113) of the randomized controlled CLUSTER trial. During a 72-week period, patients received open-l...

see more →

Guidelines  1 results

Consensus protocols for the diagnosis and management of the hereditary autoinflammatory...
Pediatric Rheumatology Online Journal; Hansmann S, Lainka E et. al.

Feb 19th, 2020 - Rare autoinflammatory diseases (AIDs) including Cryopyrin-Associated Periodic Syndrome (CAPS), Tumor Necrosis Receptor-Associated Periodic Syndrome (TRAPS) and Mevalonate Kinase Deficiency Syndrome (MKD)/ Hyper-IgD Syndrome (HIDS) are genetically ...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  3 results

Quality of Life in Patients With Auto-inflammatory Diseases

Jul 2nd, 2020 - Recent understanding of the physiopathological mechanisms that underpin autoinflammatory diseases (AIDs) allowed a revolution in the therapeutic management of these patients, particularly through the use of biotherapies. However new treatments nee...

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

May 17th, 2018 - This study consists of 3 randomized cohorts (one per condition of colchicine resistant/intolerant Familial Mediterranean Fever (crFMF), Hyper Immunoglobulin D Syndrome (also known as mevalonate kinase deficiency (HIDS/MKD), and Tumor Necrosis Fact...


Jan 31st, 2013 - Background: Genetics is suggested to play a critical role in the development of Behçet's disease (BD). Shared phenotypic features requires an approach to the differential diagnosis from periodic febrile syndromes particularly from mevalonate kinas...

see more →

News  7 results

FDA Approves Canakinumab (Ilaris), First Drug for Adult-Onset Still's Disease

Jun 19th, 2020 - The Food and Drug Administration has expanded the indications for canakinumab (Ilaris) to include all patients with active Still's disease older than 2 years, adding adult-onset Still's disease (AOSD) to a previous approval for juvenile-onset Stil...

FDA makes Ilaris the first approved treatment for adult-onset Still’s disease
Christopher Palmer

Jun 18th, 2020 - The Food and Drug Administration has expanded the indications for canakinumab (Ilaris) to include all patients with active Still’s disease older than 2 years, adding adult-onset Still’s disease (AOSD) to a previous approval for juvenile-onset Stil.

NHS England Funds 'Life-Changing' Treatment for Periodic Fever Syndromes

Mar 4th, 2020 - NHS England is funding a 'life-changing treatment' for certain individuals with periodic fever syndromes (PFS), a group of rare conditions characterised by fever, joint pains and swelling. Patients with PFS often experience inflammatory 'flares' i...

Fever Syndromes Show Dramatic Response to IL-1 Blocker

May 16th, 2018 - Action Points Note that three randomized trials, in different populations of patients with monogenic autoinflammatory diseases, showed a dramatic response to the (IL)-1β antibody canakinumab compared with placebo. One advantage to the drug is the ...

Canakinumab (Ilaris) Gets FDA Nod for Three Rare Periodic Fever Syndromes

Sep 26th, 2016 - The US Food and Drug Administration (FDA) has approved three new indications for the interleukin-1-β inhibitor canakinumab (Ilaris, Novartis). They are tumor necrosis factor receptor–associated periodic syndrome (TRAPS), hyperimmunoglobulin D synd...

see more →